Capricor Therapeutics Stock Tanks 54% Over FDA Panel's Negative Vote On Deramiocel Effectiveness
Capricor Therapeutics (CAPR) shares fell about 54% after an FDA Cellular, Tissue and Gene Therapies Advisory Committee voted that available evidence did not support Deramiocel’s effectiveness for cardiomyopathy in Duchenne muscular dystrophy. The stock was around $3.03 on Thursday, down from $6.57 the prior close on Nasdaq.
How this was made
The 30-second read
Why it matters
A negative advisory vote is a high-signal regulatory risk event that can delay or complicate approval prospects and shift investor expectations for the clinical evidence package.
Market read
Traders can treat this as a fresh regulatory catalyst driving immediate repricing and heightened event risk for CAPR.
What to watch
The article does not detail the specific evidence deficiencies or whether additional analyses/subgroup data could change the FDA’s view, leaving room for narrative-driven volatility.
Background
FDA’s Cellular, Tissue and Gene Therapies Advisory Committee reviewed Deramiocel for cardiomyopathy in Duchenne muscular dystrophy.
Ticker impact
Capricor Therapeutics shares fell about 54% after an FDA advisory committee voted Deramiocel evidence did not support effectiveness in Duchenne cardiomyopathy.
Further downside risk and elevated volatility are likely until the company clarifies next regulatory steps and data package.
The article cites a specific FDA advisory committee vote against Deramiocel effectiveness, which is a direct, catalyst-driven risk event for CAPR.
Market effects
Highlights heightened scrutiny for gene and cell therapies where effectiveness evidence is questioned by FDA advisory panels.
Limited, primarily impacts US-listed biotech sentiment around FDA advisory outcomes.
Moderate, as FDA advisory decisions can influence global investor risk appetite for similar DMD cardiomyopathy programs.
Counterpoint
An advisory committee vote is not a final FDA decision, so CAPR could rebound if the company has a credible path to address evidence gaps.
Key entities
- companyCapricor Therapeutics, Inc.
US biotech whose stock is reacting to the FDA advisory committee vote on Deramiocel effectiveness.
- productDeramiocel
Cell therapy evaluated for cardiomyopathy in patients with Duchenne muscular dystrophy.
- regulatorFDA Cellular, Tissue and Gene Therapies Advisory Committee
Advisory body whose vote concluded available evidence did not support Deramiocel effectiveness.
